Healthequity stock jumps on better-than-expected earnings and bullish outlook

HealthEquity Inc. (HQY) shares jumped 7.6% in after-hours trading following a strong second fiscal quarter that exceeded Wall Street expectations and prompted raised full-year earnings guidance. The company reported adjusted EPS of $1.08, a 26% year-over-year increase, and revenue of $325.8 million, both surpassing consensus, driven by 9% revenue growth, record 71% gross margins, and 18% adjusted EBITDA growth to $151.1 million. This performance, coupled with a 12% rise in HSA assets to $33.1 billion and management's highlighting of legislative tailwinds for HSAs, reinforced investor confidence in the company's execution and market position.

Analysis

HealthEquity, Inc. (HQY) reported a robust second fiscal quarter, triggering a 7.6% after-hours share price increase, driven by a significant beat on earnings and a positive outlook. The company posted adjusted EPS of $1.08, a 26% year-over-year increase that comfortably surpassed the analyst consensus of $0.92. Revenue grew 9% to $325.8 million, also exceeding expectations. Critically, the firm demonstrated strong operational leverage and profitability, achieving a record gross margin of 71% and expanding its adjusted EBITDA margin to 46% of revenue, up from 43% in the prior-year period. This efficiency translated into an 18% rise in adjusted EBITDA to $151.1 million. The financial outperformance is underpinned by solid growth in core business metrics, including a 6% increase in Health Savings Accounts (HSAs) to 10 million and a 12% rise in total HSA assets to $33.1 billion. Management's confidence is further reflected in its decision to raise full-year 2026 adjusted EPS guidance to a range of $3.74-$3.91, placing the midpoint above consensus. This financial strength is complemented by a shareholder-friendly capital return policy, with $66 million in share repurchases during the quarter, and a significant external tailwind noted by the CEO regarding the largest legislative expansion for HSAs since 2006.

Key Decisions for Investors

• Given the strong beat-and-raise quarter, record margin expansion, and positive EPS guidance, investors could view the results as a validation of the company's operational execution and growth trajectory.
• The commentary on legislative tailwinds for HSAs presents a significant long-term catalyst; investors should monitor policy developments and their potential to accelerate account and asset growth beyond current projections.
• While the earnings performance is strong, note that the full-year revenue guidance was only in-line with expectations, suggesting investors should weigh the impressive profitability gains against top-line growth forecasts when assessing valuation.
• Consider the company's balanced capital allocation, where continued share buybacks ($351.8 million remaining authorization) signal management's confidence and provide a source of shareholder return alongside investments in growth.